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Abstract 
 
Objective: The objective of this systematic review is to determine whether or not Sodium 
Oxybate is a safe and effective treatment of pain and sleep-related symptoms of fibromyalgia. 
 
Study design: Review of three English language primary randomized controlled trials published 
between 2003-2010. 
 
Data Sources: Randomized, controlled clinical trials comparing Sodium Oxybate to a placebo 
group were found using PubMed and Cochrane database. 
 
Outcome Measured: Disease improvement and adverse effects (nausea). Disease improvement 
was measure using Disease the Tender point index (TPI) (rated 0-4), subjective daily 
assessments of pain /fatigue, PVAS score (0= no pain, 100= worst possible pain), FVAS score 
(0= no fatigue, 100= worst possible fatigue), Fibromyalgia Impact Questionnaire (FIQ) (rated 1-
100), The Jenkins Scale for sleep (JSS) (rated 1-20), a quality-of-life questionnaire (SF-36) 
(rated 1-100), Patient Global Impression of Change (PGI-C), Tender Point Count (TPC) (rated: 
0-18), Clinical Global Impression of Change (CGI-S), Epworth Sleepiness Scale  (ESS) (rated: 
1-24), and Functional Outcome of Sleep Questionnaire (FOSQ) (rated: 5-20). Adverse effects 
(nausea) were measured using incidence of cases reported. 
 
Results: Three randomized controlled trials were included in this review. The higher dose of 
Soidum Oxybate (6.0g/day) was shown to be more effective than the lower dose (4.5g/day) at 
relieving fibromyalgia symptoms.  Although the higher dose of Sodium Oxybate was more 
effective, nausea was more commonly experiences in this group than the group given the lower 
daily dose. 
 
Conclusion: The results of the randomized controlled trials reviewed demonstrated that Sodium 
Oxybate 6.0 g/day was more effective than the 4.5g/day dosage at improving fibromyalgia 
symptoms. However due the adverse effect of nausea 4.5g/day is a safe starting dose for patients.  
The relatively low incidence of  nausea encourages its use in fibromyalgia. Further studies 
should be done regarding the titration from doses 4.5g/day to 6.0g/day to see if the adverse effect 
of nausea has a lower incidence. 
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Introduction 
Fibromyalgia syndrome (FMS) is a long-term chronic pain syndrome affecting an 
estimated 5% of Americans.1 The syndrome is characterized by widespread pain affecting joints, 
muscles, tendons, bones, and various soft tissues.1 Other features common to FMS include 
insomnia, fatigue, stiffness, headaches, cognitive changes, affective symptoms, and IBS 
symptoms.2  FMS is a common disorder, affecting about 3-6 million people in the US 
population.2 The syndrome is seen most commonly in adult females between the ages of 20-50.3 
Patients seek care in efforts to determine the source of such widespread deep chronic pain and to 
palliate the pain. Practitioners then order various expensive diagnostic studies such as lab work 
and multiple imaging studies, all of which will be negative in FMS, working towards a diagnosis 
of exclusion. As a result, total healthcare costs over a 12 month period were about three times 
higher in FMS patients than the mean (SD) at about $9573 vs. $3291.4 It was determined that 
patients with FMS are seen in an out-patient setting about 10 times a year and about 25 times in 
the year preceding their diagnosis with FMS.4 
FMS is a diagnosis of exclusion; however, the American College of Rheumatology has 
designated 18 sites on the body as possible tender points to aid in the diagnosis of fibromyalgia. 
There is no cure for this painful syndrome. The etiology is unclear but researchers have noted 
that symptoms tend to begin after an infection, physical trauma, or due to psychological stress.2 
More commonly, FMS symptoms are seen as a gradual onset of widespread pain that continues 
to worsen with no single event attributable. The pathogenesis is also not well understood. 
However, it is believes that there is a genetic predisposition for FMS causing an imbalance and 
disregulation of various neurotransmitter functioning.3 FMS is thought to be a central 
sensitization problem, where the patient with FMS has an amplified perception of pain due 
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improper processing of pain signals in the brain. Because there is no clear etiology there is 
controversy regarding the best way to treat the symptoms of FMS.3 
Various medication have been tried to treat this central pain disorder. Medications 
include, tricyclic antidepressants, cyclobenzaprine, tizanidine, SSRIs, SNRIs, gabapentin, 
NSAIDs, oral corticosteroids, and tramadol. Currently, the only pharmacologic therapy 
specifically indicated for FMS is Lyrica (pregabalin).2  Non-pharmacologic therapy includes 
cardiovascular exercise, cognitive behavioral therapy, and patient education.2  Management 
goals are aimed towards pain relief, increase in the quality of sleep, and increase in physical 
functioning. 
The treatment options that have been listed above are all efficacious means of treating 
FMS. However, as with all treatment options there are different effects on various populations of 
patients.  Sodium Oxybate is a metabolite of the inhibitory neurotransmitter, GABA.1 It is 
currently approved to treat narcoleptics with symptoms of cataplexy and excessive daytime 
sleepiness.3 This treatment method was shown to be effective in patients with such symptoms 
because it works to consolidate fragmented sleep and decrease the number of night time 
awakenings.3 Researchers noted in the studies regarding the efficacy of Sodium Oxybate in those 
with narcolepsy, that patients with the comorbiditiy of FMS had improvement of their pain and 
sleep related complaints as well.3 Thus, it was proposed that Sodium Oxybate may be effective 
in patients with FMS.   
Objective 
The objective of this selective EBM review is to determine whether or not Sodium 
Oxybate is a safe and effective treatment for patients with fibromyalgia. The use of Sodium 
Grandinette, Sodium Oxybate & FMS 3 
Oxybate has been shown to be effective in the treatment of the symptoms of fatigue, quality of 
sleep, and pain in patients with FMS. 
Methods 
 All three trials used met the following criteria. Participants had to be over the age of 18 
with a diagnosis of FMS, determined by the American College of Rheumatology criteria. The 
intervention used was Sodium Oxybate of either a dose of 4.5 g/day or 6.0 g/day.  The treatment 
groups receiving Sodium Oxybate were compared to those receiving a control treatment. 
Outcomes measured were the reduction in symptoms associated with FMS, including fatigue, 
pain, quality of sleep, and adverse effects (nausea); which are patient oriented evidence that 
matters (POEM). The types of studies used were randomized controlled trials, all of which are 
compared to a placebo comparison group. 
 In both the Moldofsky et al and Russel et al primary literature, studies were designed in 
similar fashion.  Eligibility was determined and participants completed a 39 day “washout 
period” from prescription medications that need to be discontinued. Participants then began a two 
week period where their PVAS scores submitted three times daily to determine FMS participants 
baseline. Both studies randomized participants into three group of either placebo, 4.5g/day, or 
6.0g/day doses administered at bedtime for a period of 8 weeks.1,2 During the study there were 
three treatment visits to assess efficacy.  In the Scharf et al study, patients we randomized to one 
of two groups and received either 6.0 g/day sodium oxybate or placebo for one month, with an 
intervening two week washout period.3 Participants were then switched to the opposite group and 
tested for another month. The efficacy was assessed at the end of both month periods. 
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Key words used in literature search were fibromyalgia, Sodium Oxybate, sleep, pain, 
fatigue, and quality of sleep. All articles were published in the English language in peer reviewed 
journals after the year of 2003. Literature searches occurred via PubMed and Medline using 
Cochrane databases.  Articles were selected based on the relevance of the outcomes in the 
patients with FMS (POEMs). Studies that were included were those that were double blind, 
randomized, and placebo controlled, and based on the outcome that was important to the patient. 
Those excluded were studies that included patients under the age of 18 years. Statistics reported 
in these studies were relative benefit increase (RBI), absolute benefit increase (ABI), numbers 
needed to treat (NNT), numbers needed to harm (NNH), p-values, and change from baseline. 
Outcomes measured were those of patient oriented evidence that matters. Disease 
improvement was measured using the Tender Point Index (TPI) (rated 0-4), subjective daily 
assessments of pain /fatigue, PVAS score (0= no pain, 100= worst possible pain), FVAS score 
(0= no fatigue, 100= worst possible fatigue), Fibromyalgia Impact Questionnaire (FIQ) (rated 1-
100), The Jenkins Scale for sleep (JSS) (rated 1-20), a quality-of-life questionnaire (SF-36) 
(rated 1-100), Patient Global Impression of Change (PGI-C), Tender Point Count (TPC) (rated: 
0-18), Clinical Global Impression of Change (CGI-S), Epworth Sleepiness Scale  (ESS) (rated: 
1-24), and Functional Outcome of Sleep Questionnaire (FOSQ) (rated: 5-20). Adverse effects 
(nausea) were measured based on the incidence reported per patient. Table 1 demonstrates the 
demographics included in the studies. 
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Table 1: Characteristics of Studies Included for Analysis of Sodium Oxybate in the Treatment of 
FMS 
Study/ 
type 
#Pts/age  Inclusion criteria Exclusion criteria W/D Interventions 
Moldofsky; 
2010 (1) 
 
 
 
RCT 
151 pts 
 
 
 
18+ 
PVAS greater than 4 
(scale of 1-10) 
 
Discontinued used of 
opiates, antidepressants, 
cyclobenzaprine, 
tramadol.  
Presence of inflammatory rheumatic 
disease, thyroid disease, seizures; Apnea 
hypopnea index of >15/hour on screening 
polysomnogram; History of head trauma 
resulting in LOC, migraines, intracranial 
surgery, substance abuse, succinic 
semialdehyde dehydrogenase deficiency ; 
Use of specific drugs within 30 prior to 
screening; Serum creatine of >2.0 mg/dl, 
abnormal LFTs/EKG , pregnancy; 
Occupations that required night shift 
work 
 44 Sodium 
Oxybate 
4.5g/day and 
6.0g/day 
Russell; 
2009 (2) 
 
 
RCT 
188 pts  
 
 
18+ 
Mean score PVAS >40  
(on a 0-100 VAS scale) 
for up to 2 weeks before 
randomization 
 
Required discontinuation 
of opiates, antidepressants, 
cyclobenzaprine, 
tramadol. 
Presence of inflammatory rheumatic 
disease, thyroid disease, seizures; Apnea 
hypopnea index of >15/hour on screening 
polysomnogram; History of head trauma 
resulting in LOC, migraines, intracranial 
surgery, substance abuse, succinic 
semialdehyde dehydrogenase deficiency ; 
Use of specific drugs within 30 prior to 
screening; Serum creatine of >2.0 mg/dl, 
abnormal LFTs/EKG , pregnancy; 
Occupations that required night shift 
work 
 42 Sodium 
Oxybate: (in 
oral solution) 
4.5 gm/night 
6.0 gm/night 
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Scharf MB; 
2003 (3) 
 
 
RCT 
24 pts 
 
 
 
18+ 
Confirmed diagnosis of 
FMS 
History of widespread 
pain/tiredness and pain at 
11/18 tender point sites 
 
Alpha intrusion in a mean 
of at least 30% of non 
REM epochs on 2 of 3 
nights of the pre-
Treatment PSG 
evaluations 
 
Patients who have never 
taken sodium oxybate 
N/A  3 Sodium 
Oxybate 
6.0g/day 
 
Results 
 The results were presented in dichotomous form for studies done by Russel et al and 
Scharf et al, while Results for Moldofsky et al were reported in continuous form. Russel et al 
demonstrated 34.5% in the Sodium Oxybate group and a 12.5% in the placebo group achieved a 
20% criteria improvement of primary outcome variable (POV) being pain.2 The test was seen to 
be statistically significant (P < 0.05). The relative benefit increase (RBI) was calculated to be 
182% and the absolute benefit increase was 20%. This study determines that the number needed 
to treat (NNT) was 5 for the treatment of Sodium Oxybate being 4.5g/day compared to placebo 
(Table 2). 
 Scharf et al showed that the testing was statistically significant ( P<0.05). In regards to 
“morning alertness” the absolute benefit increase was shown to be 6% and the relative benefit 
increase was 800%. Numbers needed to treat was determined to be 17 for those receiving 
6.0g/day. In regards to “sleep quality” the absolute benefit increase was shown to be 23% and the 
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relative benefit increase was 230%. Numbers needed to treat was determined to be 5 for those 
receiving 6.0g/day compared to placebo (Table 2). 
 Moldofsky et al analyzed both daytime sleepiness and sleep quality at both 4.5g/day and 
6.0g/day doses. The data was reported in dichotomous data. The mean baseline for daytime 
sleepiness was 11.2 and placebo improved from baseline by -1.0 while the 4.5g/day treatment 
group improved by -3.1 and the 6.0g/day treatment group improved by -4.7 from baseline.1 The 
mean baseline for sleep quality was 16.6.1 The placebo group improved from baseline by -3.8 
and the 4.5g/day treatment group improved by -7.1 and the 6.0g/day treatment group improved 
by -8.4 from baseline (Table 2).1 
 
Table 2: Efficacy of Sodium Oxybate on Improving FMS symptoms 
Study Symptoms Therapy 
dosage 
Statistical data 
   P-value RBI ABI NNT 
Russel Reduction of pain 4.5g/d 0.007 182% 20% 5 
Scharf Morning alertness 6.0g/d 0.0033 800% 6% 17 
 Sleep quality 6.0 g/d 0.0003 230% 23% 5 
   Baseline 
mean 
Placebo: change in 
baseline 
Tx: Improvement from 
baseline 
Moldofsky Daytime sleepiness 4.5g/d 11.2 -1.0 -3.1 
 Daytime sleepiness 6.0g/d 11.2 -1.0 -4.7 
 Sleep quality 4.5g/d 16.6 -3.8 -7.1 
 Sleep qualiry 6.0g/d 16.6 -3.8 -8.4 
 
RBI= Relative Benefit Increase   ABI= Absolute Benefit Increase   NNT= Numbers 
Needed to treat 
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One of the most common treatment emergent adverse effects experienced in two of the 
trials was that of nausea. There was an incident of 16.7% in both the Russel et al and Moldofsky 
et al treatment groups, and only a 9.23% incidence in the placebo groups.1,2  The symptom of 
nausea was describes as mild and tolerable. Nausea was more common in the Sodium Oxybate 
treatment group than in the placebo group. There was no data notation regarding adverse events 
in the Scharf et al study (Table 3). 
 
 
 
 
 
 
 
 
 
Table 3: Incidences of Nausea in Sodium Oxybate vs. Placebo Group 
Study Incidences of 
nausea in 
treatment 
group 
Incidences of 
nausea in 
control group 
p-value RRI ARI NNH 
Russel 10/60 
(16.7%) 
6/65 
(9.23%) 
0.02 88 8 13 
Moldofsky 10/60 
(16.7%) 
6/65 
(9.23%) 
0.02 88 8 13 
Scharf - - - - - - 
 
RRI= Relative Risk Increase  ARI= Absolute Risk Increase  NNH= Numbers Needed to 
Harm 
 
Discussion 
 The randomized controlled trials on the study of the efficacy and safety of Sodium 
Oxybate on the treatment of FMS demonstrated that 6.0g/day was shown to be more effective in 
relieving symptoms of pain and sleep related symptoms than 4.5g/day. However the concern 
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with the higher dosing of Sodium Oxybate would be the intolerable adverse reaction of nausea 
which caused a significant amount of participants in the 6.0 g/day treatment group to withdrawal. 
Therefore, despite the greater efficacy of 6.0g/day, the 4.5g/day seemed to outweigh the greater 
efficacy with the safer adverse reaction profile. However, patients from both groups stated the 
efficacy of Sodium Oxybate therapy at either dosage was superior to any other previous 
pharmacological therapy they had tried previously.3 The treatment of 4.5g/day is an effective 
starting dose in the treatment of symptoms related to FMS. However, the therapy can be 
increased to 6.0g/day if adverse effects are tolerable. Both therapies are safe and effective forms 
of treatment of FMS.  
 
 
Conclusion 
 Sodium Oxybate was shown to be effective and safe in the treatment of fibromyalgia. 
Results were able to show significant improvement in participants’ complaints of pain and sleep 
related symptoms. It was demonstrated that 4.5g/day is a safe and effective starting dose, and 
that 6.0g/day is a more efficacious therapy, but with a greater side effect profile. Overall, Sodium 
Oxybate demonstrated low number of treatment emergent adverse effects, especially with the 
4.5g/day therapy, indicating the therapy to be a safe and tolerable therapy. Examining the 
methods used, limitation of the studies suggest a possible higher response rate could have been 
seen with stricter monitoring of patient compliance. Patients were expected to administer their 
therapy in the evening and then another dose 2-4 hours after the initial dose. It is possible if the 
administration timeframe was more standard there would be more consistent results. However, 
the studies did not comment on the non-compliance of the medication administration and results 
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demonstrated a high response rate, regardless. Further studies could be performed to determine 
how a titration effect from a lower dose of Sodium Oxybate up to 6.0g/day would change the 
side effect profile, if at all. This would possibly decrease the amount of patients needing to 
withdrawal from the study and result in data demonstrating a more effective and tolerable 
therapy.  
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